REFERENCES
1. Chughtai B, Forde JC, Thomas DD, et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031.
2. Chen X, Yang S, He Z, et al. Comprehensive analysis of the global, regional, and national burden of benign prostatic hyperplasia from 1990 to 2021. Sci Rep. 2025;15:5644.
3. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36. 403-15, v.
4. Zou J, Talluri R, Shete S. Approaches to estimate bidirectional causal effects using Mendelian randomization with application to body mass index and fasting glucose. PLoS One. 2024;19:e0293510.
5. Varathan P, Gorijala P, Jacobson T, et al. Integrative analysis of eQTL and GWAS summary statistics reveals transcriptomic alteration in Alzheimer brains. BMC Med Genomics. 2022;15:93.
6. Porcu E, Rüeger S, Lepik K, Santoni FA, Reymond A, Kutalik Z; eQTLGen Consortium, BIOS Consortium. Mendelian randomization integrating GWAS and eQTL data reveals genetic determinants of complex and clinical traits. Nat Commun. 2019;10:3300.
7. Sun Y, Liu Y, Dian Y, Zeng F, Deng G, Lei S. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials. Int J Surg. 2024;110:4688-94.
8. Mullin BH, Tickner J, Zhu K, et al. Characterisation of genetic regulatory effects for osteoporosis risk variants in human osteoclasts. Genome Biol. 2020;21:80.
9. Chauquet S, Zhu Z, O'Donovan MC, Walters JTR, Wray NR, Shah S. Association of antihypertensive drug target genes with psychiatric disorders: a Mendelian randomization study. JAMA Psychiatry. 2021;78:623-31.
10. Finan C, Gaulton A, Kruger FA, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:eaag1166.
11. Xu G, Dai G, Huang Z, Guan Q, Du C, Xu X. The etiology and pathogenesis of benign prostatic hyperplasia: the roles of sex hormones and anatomy. Res Rep Urol. 2024;16:205-14.
12. Wang SY, Cai Y, Hu X, et al. P. gingivalis in oral-prostate axis exacerbates benign prostatic hyperplasia via IL-6/IL-6R pathway. Mil Med Res. 2024;11:30.
13. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol. 2021;206:806-17.
14. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338:557-63.
15. Roehrborn CG, Bruskewitz R, Nickel JC, et al.; Proscar Long-Term Efficacy and Safety Study Group. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171:1194-8.
18. Yang Q, Peters T, Donovan J, Wilt T, Abrams P. Transurethral incision compared with transurethral resection of the prostate for bladder outlet obstruction: a systematic review and meta-analysis of randomized controlled trials. J Urol 2001;165:1526-32.
19. Wu X, Lv D, Lei M, et al. A 10-gene signature as a predictor of biochemical recurrence after radical prostatectomy in patients with prostate cancer and a Gleason score ≥7. Oncol Lett. 2020;20:2906-18.
20. Shi YF, Yu DJ, Jiang CY, et al. TRAF6 regulates proliferation of stromal cells in the transition and peripheral zones of benign prostatic hyperplasia via Akt/mTOR signaling. Prostate. 2018;78:193-201.
21. Liu J, Zhou W, Yang L, et al. STEAP4 modulates cell proliferation and oxidative stress in benign prostatic hyperplasia. Cell Signal. 2024;113:110933.
22. Binmahfouz LS, Almukadi H, Alamoudi AJ, et al. 6-paradol alleviates testosterone-induced benign prostatic hyperplasia in rats by inhibiting AKT/mTOR axis. Plants. 2022;11:2602.
23. Jiang X, Wang J, Chen P, et al. [6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K/AKT signaling. Cancer Cell Int. 2021;21:420.
24. El-Maadawy WH, Hassan M, Abdou RM, et al. 6-paradol alleviates diclofenac-induced acute kidney injury via autophagy enhancement-mediated by AMPK/AKT/mTOR and NLRP3 inflammasome pathways. Environ Toxicol Pharmacol. 2022;91:103817.
25. Li C, Hu WL, Lu MX, Xiao GF. Resveratrol induces apoptosis of benign prostatic hyperplasia epithelial cell line (BPH-1) through p38 MAPK-FOXO3a pathway. BMC Complement Altern Med. 2019;19:233.
26. Wang Z, Yang S, Li Y, et al. Simvastatin improves benign prostatic hyperplasia: role of peroxisome-proliferator-activated receptor-γ and classic WNT/β-catenin pathway. Int J Mol Sci. 2023;24:4911.
27. Funahashi Y, Wang Z, O’Malley KJ, et al. Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. Prostate. 2015;75:381-9.
28. Chen Y, Xu H, Liu C, et al. LncRNA DIO3OS regulated by TGF-β1 and resveratrol enhances epithelial mesenchymal transition of benign prostatic hyperplasia epithelial cells and proliferation of prostate stromal cells. Transl Androl Urol. 2021;10:643-53.
29. Kim HJ, Jin BR, An HJ. Hesperidin ameliorates benign prostatic hyperplasia by attenuating cell proliferation, inflammatory response, and epithelial-mesenchymal transition via the TGF-β1/Smad signaling pathway. Biomed Pharmacother. 2023;160:114389.
30. Vickman RE, Aaron-Brooks L, Zhang R, et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat Commun. 2022;13:2133.
31. Zhang T, Mao C, Chang Y, Lyu J, Zhao D, Ding S. Hypoxia activates the hypoxia-inducible factor-1α/vascular endothelial growth factor pathway in a prostatic stromal cell line: a mechanism for the pathogenesis of benign prostatic hyperplasia. Curr Urol. 2024;18:185-93.
32. Consoli V, Burò I, Gulisano M, et al. Evaluation of the antioxidant and antiangiogenic activity of a pomegranate extract in BPH-1 prostate epithelial cells. Int J Mol Sci. 2023;24:10719.
33. Lekas AG, Lazaris AC, Chrisofos M, et al. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology. 2006;68:436-41.
34. Kim EY, Jin BR, Chung TW, et al. 6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis. BMB Rep. 2019;52:560-5.
35. Abdel-Aziz AM, Gamal El-Tahawy NF, Salah Abdel Haleem MA, Mohammed MM, Ali AI, Ibrahim YF. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFβ and iNOS/COX-2. Eur J Pharmacol. 2020;889:173631.
36. Trujillo-Rojas L, Fernández-Novell JM, Blanco-Prieto O, Rigau T, Rivera Del Álamo MM, Rodríguez-Gil JE. The onset of age-related benign prostatic hyperplasia is concomitant with increased serum and prostatic expression of VEGF in rats: potential role of VEGF as a marker for early prostatic alterations. Theriogenology. 2022;183:69-78.
37. Yang Y, Sheng J, Hu S, et al. Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis. Cell Death Dis. 2022;13:533.
38. Liu Z, Li S, Chen S, et al. YAP-mediated GPER signaling impedes proliferation and survival of prostate epithelium in benign prostatic hyperplasia. iScience. 2024;27:109125.
39. Shi X, Peng Y, Du X, et al. Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells. Prostate. 2017;77:1424-37.
40. Wynder JL, Nicholson TM, DeFranco DB, Ricke WA. Estrogens and male lower urinary tract dysfunction. Curr Urol Rep. 2015;16:61.
41. Wang Z, Hu L, Salari K, et al. Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. J Pathol. 2017;243:457-67.
42. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011;82:184-99.
43. Liu W, Rodgers GP. Olfactomedin 4 in cancer development and progression. Biochim Biophys Acta Rev Cancer. 2025;1880:189423.
44. Hata J, Harigane Y, Matsuoka K, et al. Mechanism of androgen-independent stromal proliferation in benign prostatic hyperplasia. Int J Mol Sci. 2023;24:11634.
